Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05333549
PHASE2

Istradefylline for Parkinson Disease With Cognitive Impairment

Sponsor: Virginia Commonwealth University

View on ClinicalTrials.gov

Summary

The purpose of this research study is to determine whether istradefylline improves cognition in individuals with Parkinson disease with cognitive impairment.

Official title: Istradefylline for Parkinson Disease Cognitive Impairment

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2022-07-18

Completion Date

2025-06-09

Last Updated

2026-09-23

Healthy Volunteers

No

Interventions

DRUG

Istradefylline medication

2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications

Locations (1)

Virginia Commonwealth University

Richmond, Virginia, United States